Aurobindo Pharma's profit in April-June quarter may rise 29.6 percent Y-o-Y to Rs 560.3 crore and revenue is hoped to rise 15 percent to Rs 3,810.7 crore. Operating profit is likely to increase 24.1 percent to Rs 899.2 crore and margin may expand 180 basis points to 23.6 percent Y-o-Y.
Expectations:
- Revenue growth may be led by uninterrupted traction in the US -US business is approximately 58 percent of formulation sales.
- US business will hopefully grow around 30 percent Y-o-Y on the back of 30 new drug launches over past 1 year.
- Company got 13 approvals from drugs in Q1FY17 itself -Generic versions of Tricor, Valcyte, Vimpat, Vfend & injectable Eptifitabine may drive US growth.
- Europe sales bounced back in Q4FY16 to 9 percent growth, nonetheless depreciation of pound & euro may weigh in June quarter.
- Antiretroviral (ARV) drugs sales have been lumpy. Analysts expect around 5-6 percent growth atleast Y-o-Y
Presently Aurobindo Pharma share price is trading at a decline of 0.46%at Rs. 746.70. We are yet to see what effect the revised Q1 numbers will have on this stock. It opened at Rs. 750.00 against its previous closing at Rs. 750.15.
Aurobindo Pharma is one of the top 500 stocks identified by Dynamic Levels research team for this quarter out of the 1700 shares listed on NSE. Aurobindo Pharma share price met its 52 week high on 891.50 on 30th Dec ‘15 while the 52 week low is seen at Rs. 582.00 on 25th Feb ‘16. As per 23rd August 7lakh shares are traded in the counter with a traded value of Rs. 5849.80 lakhs as per NSE. The Average Daily Movement of the stock is 24.43 and its average volume for last 20 days is 1489090.
For further details refer to Aurobindo Pharma share price forecast.
No comments:
Post a Comment